CD274 and cancer: Immune checkpoint inhibitors (ICI) are monoclonal antibodies that block these pathways by binding to the PD-1 receptor (i.e., nivolumab, pembrolizumab), to PD-L1 (i.e., atezolizumab), or to CTLA-4 (i.e., ipilimumab) and thus enhance the immune response against cancer cells.